Epigenic Therapeutics, a China-based biotechnology startup dedicated to developing next-generation gene modulation therapy utilising epigenome regulation to treat prevalent diseases, has raised $32 million in Series A round of financing co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital.

This round of financing will support the preclinical development and early clinical validation of two leading programmes, discovery of future pipelines, expansion of the leadership team, and continued investments in the company's core technology platforms.

Epigenic's EPIREG technology offers a compelling alternative to the traditional cleavage-dependent gene editing tools by which altering the DNA sequence would raise safety concerns. By precisely modulating gene expression(s) at epigenetic levels, EPIREG is expected to achieve potent and durable silencing of target gene(s) to provide revolutionary and novel solutions to patients with chronic diseases.

"In two years since the inception, Epigenic has made significant progress towards transforming cutting-edge science into life-saving epigenome medicines. Now we have developed targeted therapeutic strategies." said Bob Zhang, Co-founder and CEO of Epigenic Therapeutics.